2
|
Lilyquist J, Laduca H, Hu C, Na J, Polley EC, Hart SN, Pesaran T, Tippin-Davis B, Goldgar DE, Dolinsky JS, Couch FJ. Abstract P6-09-02: Associations between hereditary cancer panel predisposition genes and breast cancer histological subtypes. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Clinical panel testing has become routine practice for patients that are diagnosed with breast cancer at a young age and/or have a personal or family history of cancer. Associations with known breast cancer genes and breast cancer subtypes have been previously identified, such as BRCA1 associations with estrogen receptor negative (ER-) and triple negative (ER-/PR-/HER2-) breast cancers. However, the cancer predisposition genes associated with each of the four clinical subtypes of breast cancer have not been fully defined. We evaluated 24,901 Caucasian female breast cancer cases receiving clinical panel testing for 23 cancer predisposition genes and assessed associations between mutations in each gene and breast cancer subtypes.
Methods: Germline hereditary cancer multigene panel testing results for cancer predisposition genes were obtained for 24,901 Caucasian female breast cancer cases evaluated by a clinical testing laboratory. Information on tumor histology, personal and family history of cancer, age at diagnosis, and previous genetic testing was provided by clinical care providers of patients receiving clinical cancer genetic testing. Breast cancer cases were classified into clinical breast cancer subtypes based on estrogen/progesterone hormone receptor status (HR) and HER2 status: Luminal A (HR+/HER2-), Luminal B (HR+/HER2-), HER2 subtype (HR-/HER2+), and Triple Negative (HR-/HER2-). The frequency of pathogenic or likely pathogenic mutations observed in each subtype was compared against the Exome Aggregation Consortium (ExAC) non-TCGA non-Finnish European population to estimate risks.
Results: ATM was associated with moderate risks (odds ratio (OR)>2.0) of Luminal A, Luminal B, and HER2 subtypes of breast cancer, but was not associated with the Triple Negative subtype. PALB2 was associated with moderate risk for Luminal B subtype, but high risk (OR>5.0) for Luminal A, HER2, and triple negative subtypes. TP53 was associated with high risks for Luminal B and HER2 tumors. NBN, MRE11A, and RAD50 were not associated with any subtype of breast cancer.
Conclusions: Identifying associations between inherited mutations (odds ratio (OR)>2.0) and breast cancer subtypes can inform clinical risk management, treatment options, and therapeutic development efforts.
Citation Format: Lilyquist J, Laduca H, Hu C, Na J, Polley EC, Hart SN, Pesaran T, Tippin-Davis B, Goldgar DE, Dolinsky JS, Couch FJ. Associations between hereditary cancer panel predisposition genes and breast cancer histological subtypes [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-09-02.
Collapse
Affiliation(s)
- J Lilyquist
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - H Laduca
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - C Hu
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - J Na
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - EC Polley
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - SN Hart
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - T Pesaran
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - B Tippin-Davis
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - DE Goldgar
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - JS Dolinsky
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - FJ Couch
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| |
Collapse
|
3
|
Couch FJ, Shimelis H, LaDuca H, Hu C, Hart SN, Polley EC, Pesaran T, Tippin-Davis B, Goldgar DE, Dolinsky JS. Abstract PD1-01: Triple negative breast cancer predisposition genes. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd1-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Germline cancer testing panels provide an effective method for identifying individuals at increased risk for breast cancer. However, estimates of risk for triple negative breast cancer (TNBC) (estrogen receptor-negative, progesterone receptor-negative, HER2-negative) associated with pathogenic mutations in panel genes have not been established. We sought to define the genes that contribute to TNBC.
Methods:Germline hereditary cancer multigene panel testing results were obtained for 8,753 TNBCs evaluated by a clinical testing laboratory. Associations between pathogenic mutations in individual genes and TNBC were assessed by comparing mutation frequencies in TNBCs and in the Exome Aggregation Consortium, non-Finn European, non-Cancer Genome Atlas reference controls.
Results: Inactivating mutations in 21 known cancer predisposition genes were identified in 14.6% of TNBCs. BRCA1, BRCA2, PALB2, BARD1, and RAD51D alterations were associated with high risks (odds ratio(OR)>5.0) of TNBC and variants in BRIP1, RAD51C, MSH6, and TP53 were associated with moderate risks (OR>2). In contrast, ATM, CHEK2, NBN, and RAD50 yielded no clinically relevant risks of TNBC. Pathogenic mutations in these established non-BRCA1/2 TNBC susceptibility genes were detected in 6.3% of TNBCs. Similar trends were observed among African American TNBCs. Overall, 5.5% of TNBCs with pathogenic mutations did not meet NCCN clinical testing criteria for BRCA1/2 due to a lack of significant family history and diagnosis over the age of 60.
Conclusions: The identification of genes associated with elevated risk of TNBC will improve understanding of the etiology of this aggressive form of breast cancer and inform risk management of individuals receiving panel testing. The high frequency of pathogenic variants suggests that all patients with TNBC, regardless of age of diagnosis or family history of cancer, should be considered for multigene panel testing.
Citation Format: Couch FJ, Shimelis H, LaDuca H, Hu C, Hart SN, Polley EC, Pesaran T, Tippin-Davis B, Goldgar DE, Dolinsky JS. Triple negative breast cancer predisposition genes [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD1-01.
Collapse
Affiliation(s)
- FJ Couch
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - H Shimelis
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - H LaDuca
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - C Hu
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - SN Hart
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - EC Polley
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - T Pesaran
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - B Tippin-Davis
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - DE Goldgar
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| | - JS Dolinsky
- Mayo Clinic, Rochester, MN; Ambry Genetics, Aliso Viejo, CA; University of Utah, Salt Lake, UT
| |
Collapse
|
4
|
Pesaran T, Karam R, Huether R, Li S, Farber-Katz S, Chamberlin A, Chong H, LaDuca H, Elliott A. Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes. Int J Breast Cancer 2016; 2016:2469523. [PMID: 27822389 PMCID: PMC5086358 DOI: 10.1155/2016/2469523] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2016] [Revised: 09/04/2016] [Accepted: 09/19/2016] [Indexed: 11/17/2022] Open
Abstract
Genetic testing for hereditary breast cancer is an integral part of individualized care in the new era of precision medicine. The accuracy of an assay is reliant on not only the technology and bioinformatics analysis utilized but also the experience and infrastructure required to correctly classify genetic variants as disease-causing. Interpreting the clinical significance of germline variants identified by hereditary cancer testing is complex and has a significant impact on the management of patients who are at increased cancer risk. In this review we give an overview of our clinical laboratory's integrated approach to variant assessment. We discuss some of the nuances that should be considered in the assessment of genomic variants. In addition, we highlight lines of evidence such as functional assays and structural analysis that can be useful in the assessment of rare and complex variants.
Collapse
Affiliation(s)
- T. Pesaran
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - R. Karam
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - R. Huether
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - S. Li
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - S. Farber-Katz
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - A. Chamberlin
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - H. Chong
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - H. LaDuca
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| | - A. Elliott
- Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA
| |
Collapse
|